TOURMALINE BIO INC (TRML) Stock Income Statement
NASDAQ:TRML - Nasdaq - US89157D1054 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 89.73M | 45.41M | 76.28M | 47.51M | 22.68M | |||
| Research and Development | 66.98M | 32.37M | 56.81M | 34.25M | 15.28M | |||
| Selling, General, and Administrative Expenses | 22.75M | 13.04M | 19.47M | 13.26M | 7.41M | |||
| Operating Income | -89.73M | -45.41M | -76.28M | -47.51M | -22.68M | |||
| Interest Income/Expense | N/A | N/A | 900.00K | 800.00K | 400.00K | |||
| Other Income/Expense | 16.52M | 3.29M | 1.68M | -1.13M | -420.00K | |||
| Non Recurring Items | N/A | N/A | -200.00K | N/A | N/A | |||
| Income Before Taxes | -73.21M | -42.12M | -73.89M | -47.83M | -22.71M | |||
| Net Income | -73.21M | -42.12M | -73.89M | -47.83M | -22.71M | |||
| EBITDA | -89.69M | -45.38M | -74.90M | -46.89M | -22.23M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.89 | -8.87 | -17.93 | -11.69 | -5.51 | |||
| Non GAAP EPS | -2.87 | N/A | -17.90 | -5.53 | N/A | |||
| Statistics | ||||||||
All data in USD